Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook.

about

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook.

Item

http://www.wikidata.org/entity/Q55426703

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook.

@en

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook.

@nl

type

Item

label

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook.

@en

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook.

@nl

prefLabel

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook.

@en

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook.

@nl

P1476

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook.

@en

P2093

Athanasios Papatsoris

http://www.w3.org/2001/XMLSchema#string

Dharmesh Gopalakrishnan

http://www.w3.org/2001/XMLSchema#string

Moshe C Ornstein

http://www.w3.org/2001/XMLSchema#string

Petros Grivas

http://www.w3.org/2001/XMLSchema#string

Vadim S Koshkin

http://www.w3.org/2001/XMLSchema#string

P2860

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition

Pembrolizumab

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

The role of the CD28 receptor during T cell responses to antigen

Comprehensive molecular characterization of urothelial bladder carcinoma

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

P304

1019-1040

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S158753

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29892196

http://www.w3.org/2001/XMLSchema#string

P932

5993034

http://www.w3.org/2001/XMLSchema#string